International Business News - Celgene http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Biotechnology company Celgene Corp. said Thursday third-quarter profit surged on a boost in sales of its bone-marrow cancer treatments Revlimid and Thalomid. http://www.ibtimes.com/articles/20081023/celgene-3q-profit-surges-on-cancer-drug-sales.htm Thu, 23 Oct 2008 11:10:06 EDT Shares of Celgene Corp. rose Monday along with a recovering stock market, as the biotechnology company prepares to report third-quarter financial results and Robert W. Baird upgraded the stock. http://www.ibtimes.com/articles/20081013/celgene-shares-rise-on-upgrade-market-recovery.htm Mon, 13 Oct 2008 20:51:32 EDT Shares of Celgene Corp. climbed modestly Wednesday after Cowen and Co. upgraded the stock based on its value and strong potential for the biotechnology company's products, despite a sinking broader economy. http://www.ibtimes.com/articles/20081008/celgene-shares-rise-as-cowen-upgrades-stock.htm Wed, 08 Oct 2008 21:08:09 EDT Shares of biotechnology company Celgene Corp. rose Friday as the biotechnology company got a nod of confidence from Cowen and Co. on the sales potential for bone-marrow cancer drug Vidaza. http://www.ibtimes.com/articles/20081003/celgene-shares-rise-with-markets-vidaza-forecast.htm Fri, 03 Oct 2008 20:20:25 EDT Celgene Corp. said Thursday the Food and Drug Administration has given special status to its experimental drug for lung cancer. The company said the FDA has agreed to review Amrubican under its "fast track" program, which is designed to speed up the approval of treatments for deadly diseases. Under the program, companies can submit their applications in piecemeal fashion instead of all at once. Company scientists can also schedule special meetings to discuss their application with regulators. http://www.ibtimes.com/articles/20080904/fda-grants-celgene-cancer-drug-fast-track-status.htm Thu, 04 Sep 2008 15:52:48 EDT Among the earnings projection stories for Thursday, July 24, from AP Financial News: SUMMIT, N.J. (AP)--Biotechnology company Celgene Corp. raised its full-year profit and revenue outlook Thursday after reporting a surge in second-quarter sales from its key cancer drug Revlimid. http://www.ibtimes.com/articles/20080724/outlook-roundup-celgene-becton-dickinson.htm Thu, 24 Jul 2008 14:18:18 EDT Biotechnology company Celgene Corp. raised its full-year profit and revenue outlook Thursday after reporting a surge in second-quarter sales from its key cancer drug Revlimid. http://www.ibtimes.com/articles/20080724/celgene-boosts-2008-outlook-on-cancer-drug-sales.htm Thu, 24 Jul 2008 11:27:45 EDT Biotechnology company Celgene Corp. said Thursday its second-quarter profit more than doubled on a surge in sales of the cancer drug Revlimid. For the quarter ended June 30, the company earned $119.9 million, or 26 cents per share, compared with a profit of $54.9 million, or 13 cents per share, in the year-ago period. Excluding charges mostly related to the buyout of Pharmion Corp. in March, the company said it earned 37 cents per share. http://www.ibtimes.com/articles/20080724/celgenes-2q-profit-doubles-on-cancer-drug-sales.htm Thu, 24 Jul 2008 10:41:01 EDT Shares of biotechnology company Celgene Corp. advanced Tuesday as a potential competitor to its bone-marrow cancer treatment in Europe failed a late-stage clinical trial. http://www.ibtimes.com/articles/20080701/celgene-shares-rise-as-rivals-drug-fails-study.htm Tue, 01 Jul 2008 18:43:15 EDT Biopharmaceutical company Celgene Corp. said Monday that patients with the blood cancer multiple myeloma treated with the drug Revlimid plus a standard drug survived longer than those just taking the standard drug. http://www.ibtimes.com/articles/20080616/celgene-cancer-drug-shows-survival-benefit.htm Mon, 16 Jun 2008 12:02:31 EDT Celgene Corp. said late Sunday that a mid-stage study showed that 29 percent of patients with a certain type of blood cancer responded to its drug Revlimid. The data was presented at the American Society of Clinical Oncology meeting in Chicago. http://www.ibtimes.com/articles/20080602/celgenes-revlimid-shows-results-for-blood-cancer.htm Mon, 02 Jun 2008 08:10:37 EDT Among the earnings projection stories for Thursday, May 8, from AP Financial News: SUMMIT, N.J. (AP) _ Biotechnology company Celgene Corp. on Thursday raised its full-year sales estimate to $2.1 billion, a nearly 60 percent increase over 2007 revenue. http://www.ibtimes.com/articles/20080508/outlook-roundup-celgene-pediatrix-medical.htm Thu, 08 May 2008 14:50:29 EDT Biotechnology company Celgene Corp. on Thursday raised its full-year sales estimate to $2.1 billion, a nearly 60 percent increase over 2007 revenue. Previously, the company forecast a 30 percent increase in revenue to about $1.8 billion. http://www.ibtimes.com/articles/20080508/celgene-expects-full-year-sales-of-about-2-1-billion.htm Thu, 08 May 2008 12:14:06 EDT Biotechnology company Celgene Corp. said Thursday it swung to a loss in the first quarter, hurt by in-process research and development costs related to an acquisition. http://www.ibtimes.com/articles/20080508/celgene-swings-to-first-quarter-loss-hurt-by-r-d-costs.htm Thu, 08 May 2008 10:40:16 EDT Celgene Corp. Chairman and Chief Executive Sol J. Barer's executive compensation fell 49 percent in 2007, due to a drop in awards of stock options and restricted stock. http://www.ibtimes.com/articles/20080429/celgene-ceo-sol-j-barers-compensation-falls-49-percent.htm Tue, 29 Apr 2008 18:07:02 EDT Shares of Celgene Corp. edged higher Monday afternoon, as a Banc of America Securities analyst raised her outlook for sales of the biopharmaceutical company's cancer drug, Revlimid. http://www.ibtimes.com/articles/20080428/analysts-bullish-on-revlimid-sales-ahead-of-celgene-report.htm Mon, 28 Apr 2008 14:21:31 EDT